{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:55Z","timestamp":1791260815261,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009004","name":"Anhui University of Chinese Medicine","doi-asserted-by":"publisher","award":["HKDCCM2024003"],"award-info":[{"award-number":["HKDCCM2024003"]}],"id":[{"id":"10.13039\/501100009004","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304324"],"award-info":[{"award-number":["82304324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108295","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:22:47Z","timestamp":1781223767000},"page":"108295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synergistic dual targeting of mTOR and GLS1 overcomes glutamine-driven resistance in triple-negative breast cancer"],"prefix":"10.1016","volume":"230","author":[{"given":"Mengting","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liushun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5954-7741","authenticated-orcid":false,"given":"Wuxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.phrs.2026.108295_bib1","doi-asserted-by":"crossref","first-page":"9642","DOI":"10.1021\/acs.jmedchem.9b01035","article-title":"Development and characterization of a fluorescent probe for GLS1 and the application for high-throughput screening of allosteric Inhibitors","volume":"62","author":"Xu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108295_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115464","article-title":"Glutamine metabolism in breast cancer and possible therapeutic targets","volume":"210","author":"Li","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108295_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: a new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib4","first-page":"2832","article-title":"Suppression of transformation by and growth adaptation to low concentrations of glutamine in NIH-3T3 cells","volume":"50","author":"Rubin","year":"1990","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1083\/jcb.200703099","article-title":"Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells","volume":"178","author":"Yuneva","year":"2007","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120511","article-title":"Correlation between activation of PI3K\/AKT\/mTOR pathway and prognosis of breast cancer in Chinese women","volume":"10","author":"Deng","year":"2015","journal-title":"PLoS One"},{"issue":"3191","key":"10.1016\/j.phrs.2026.108295_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib9","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1172\/JCI69600","article-title":"Glutamine and cancer: cell biology, physiology, and clinical opportunities","volume":"123","author":"Hensley","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2026.108295_bib10","first-page":"1","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/cells8091010","article-title":"Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT\/pS6K\/pS6 in triple negative breast cancer","volume":"8","author":"Wen","year":"2019","journal-title":"Cells"},{"issue":"5-6","key":"10.1016\/j.phrs.2026.108295_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000503311","article-title":"Expression of mTOR signaling pathway molecules in triple-negative breast cancer","volume":"86","author":"Ito","year":"2019","journal-title":"Pathobiology"},{"key":"10.1016\/j.phrs.2026.108295_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113424","article-title":"Identification and optimization of 3-bromo-N\u2032-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer","volume":"219","author":"Xu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr. Opin. Cell. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1210\/me.2002-0318","volume":"17","author":"Cui","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/17460441.2017.1346608","article-title":"Stabilization of protein-protein interactions in drug discovery","volume":"12","author":"Andrei","year":"2017","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"11","key":"10.1016\/j.phrs.2026.108295_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib19","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1038\/s41467-020-18504-7","article-title":"mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability","volume":"11","author":"Gremke","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-03-0043","article-title":"Determinants of rapamycin sensitivity in breast cancer cells","volume":"10","author":"Noh","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib21","first-page":"21","article-title":"Direct-to-implant versus two-stage implant-based breast reconstruction in patients requiring postmastectomy radiotherapy","volume":"12","author":"Chuang","year":"2025","journal-title":"Plast. Aesthet. Res."},{"key":"10.1016\/j.phrs.2026.108295_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmt.2025.100119","article-title":"Multi-omics advances in understanding cancer drug resistance","volume":"12","author":"Liu","year":"2025","journal-title":"Biomed. Technol."},{"key":"10.1016\/j.phrs.2026.108295_bib23","first-page":"6","article-title":"Non-vascularised lymph node transfer: future directions for the minimally invasive surgical management of lymphoedema","volume":"12","author":"Rajaram","year":"2025","journal-title":"Plast. Aesthet. Res."},{"key":"10.1016\/j.phrs.2026.108295_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmt.2025.100100","article-title":"et. al., Advanced AI-based technologies for early detection and personalized management of cervical cancer","volume":"11","author":"Zhang","year":"2025","journal-title":"Biomed. Technol."},{"key":"10.1016\/j.phrs.2026.108295_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.breast.2020.04.004","article-title":"Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers","volume":"52","author":"Yi","year":"2020","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.phrs.2026.108295_bib26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ejca.2010.01.014","article-title":"Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study","volume":"46","author":"Zeng","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell. Metab."},{"issue":"7239","key":"10.1016\/j.phrs.2026.108295_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.molcel.2012.05.043","article-title":"Glutaminolysis activates Rag-mTORC1 signaling","volume":"47","author":"Duran","year":"2012","journal-title":"Mol. Cell."},{"issue":"34","key":"10.1016\/j.phrs.2026.108295_bib31","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1038\/s41388-022-02408-5","article-title":"Glutamine addiction promotes glucose oxidation in triple-negative breast cancer","volume":"41","author":"Quek","year":"2022","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","article-title":"Targeting cancer metabolism in the era of precision oncology","volume":"21","author":"Stine","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"22","key":"10.1016\/j.phrs.2026.108295_bib33","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.4161\/cc.22632","article-title":"Glutaminolysis feeds mTORC1","volume":"11","author":"Dur\u00e1n","year":"2012","journal-title":"Cell. Cycle"},{"issue":"6","key":"10.1016\/j.phrs.2026.108295_bib34","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1002\/jcb.26742","article-title":"Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt\/mTOR pathway in non-small cell lung cancer cells","volume":"119","author":"Gao","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib35","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acs.jmedchem.8b00961","article-title":"Overview of the development of glutaminase inhibitors: achievements and future directions","volume":"62","author":"Xu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108295_bib36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.phrs.2026.108295_bib37","doi-asserted-by":"crossref","first-page":"9342","DOI":"10.1074\/jbc.RA119.008180","article-title":"Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells","volume":"294","author":"Reis","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2026.108295_bib38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbrc.2017.02.101","article-title":"Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function","volume":"486","author":"Zhang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108295_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185092","article-title":"Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition","volume":"12","author":"Lampa","year":"2017","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.phrs.2026.108295_bib41","doi-asserted-by":"crossref","first-page":"22959","DOI":"10.1021\/acs.jmedchem.5c01841","article-title":"Design, synthesis, and biological evaluation of rapamycin derivatives as the first mammalian target of rapamycin and GLS1 dual inhibitors","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108295_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116445","article-title":"Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC\/PI3K\/AKT signal pathway","volume":"173","author":"Ye","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib43","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41467-019-08582-7","article-title":"Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production","volume":"10","author":"Waise","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2026.108295_bib44","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41422-024-01040-0","article-title":"Fueling metabolic adaptation: lysosomal AMPK ignites glutaminolysis","volume":"34","author":"Viollet","year":"2024","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108295_bib45","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.drudis.2017.08.003","article-title":"The Warburg effect and glucose-derived cancer theranostics","volume":"22","author":"Tekade","year":"2017","journal-title":"Drug. Discov. Today"},{"issue":"35","key":"10.1016\/j.phrs.2026.108295_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2512385122","article-title":"ARRDC4-mediated glycolysis enhances innate immunity to influenza A virus through fructose-1,6-bisphosphate","volume":"122","author":"Li","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s42255-023-00736-8","article-title":"PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages","volume":"5","author":"Schilperoort","year":"2023","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12935-024-03374-6","article-title":"Establishment of disulfidptosis-related LncRNA signature as biomarkers in colon adenocarcinoma","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.phrs.2026.108295_bib49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ccell.2018.05.001","article-title":"Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance","volume":"33","author":"Takahashi","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.phrs.2026.108295_bib50","doi-asserted-by":"crossref","first-page":"E893","DOI":"10.1152\/ajpendo.00484.2013","article-title":"Hypoxia-mediated carbohydrate metabolism and transport promote early-stage murine follicle growth and survival","volume":"306","author":"Makanji","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib51","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41419-025-08369-3","article-title":"Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer","volume":"17","author":"Liu","year":"2025","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.phrs.2026.108295_bib52","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41418-021-00920-x","article-title":"YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer","volume":"29","author":"Jiang","year":"2022","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.phrs.2026.108295_bib53","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/antiox11061195","article-title":"The breast cancer protooncogenes HER2, BRCA1 and BRCA2 and their regulation by the iNOS\/NOS2 axis","volume":"11","author":"Lin","year":"2022","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib54","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/s41467-023-39401-9","article-title":"SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells","volume":"14","author":"Yan","year":"2023","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.phrs.2026.108295_bib55","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.2174\/0109298673278846231222103420","article-title":"Increased ACSL6 expression predicts a favorable prognosis in triple-negative breast cancer","volume":"32","author":"Hua","year":"2025","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2026.108295_bib56","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ijc.28023","article-title":"Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors","volume":"133","author":"Figlin","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"31","key":"10.1016\/j.phrs.2026.108295_bib57","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108295_bib58","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-08-3014","article-title":"TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2","volume":"69","author":"Copp","year":"2009","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.phrs.2026.108295_bib59","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1080\/15384101.2020.1804720","article-title":"The requirement for cyclin E in c-Myc overexpressing breast cancers","volume":"19","author":"Zhou","year":"2020","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2017.12.007","article-title":"Let-7 suppresses B cell activation through restricting the availability of necessary nutrients","volume":"27","author":"Jiang","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib61","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1038\/s41467-019-12925-9","article-title":"Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.phrs.2026.108295_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202214598","article-title":"A self-assembly combined nano-prodrug to overcome gemcitabine chemo-resistance of pancreatic tumors","volume":"33","author":"Yao","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.phrs.2026.108295_bib63","article-title":"Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors","volume":"268","author":"Fu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2026.108295_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.phrs.2026.108295_bib65","doi-asserted-by":"crossref","first-page":"14609","DOI":"10.1021\/acs.jmedchem.0c00873","article-title":"Design, synthesis, and characterization of an orally active dual-specific ULK1\/2 autophagy inhibitor that synergizes with the PARP inhibitor olaparib for the treatment of triple-negative breast cancer","volume":"63","author":"Ren","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2026.108295_bib66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41422-018-0090-y","article-title":"Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis","volume":"28","author":"Zhou","year":"2018","journal-title":"Cell Res."},{"issue":"32","key":"10.1016\/j.phrs.2026.108295_bib67","doi-asserted-by":"crossref","first-page":"E2950","DOI":"10.1073\/pnas.1307736110","article-title":"Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1","volume":"110","author":"Tripathi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12951-024-02313-x","article-title":"Ginseng-derived nanoparticles alleviate inflammatory bowel disease via the TLR4\/MAPK and p62\/Nrf2\/Keap1 pathways","volume":"22","author":"Yang","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"35","key":"10.1016\/j.phrs.2026.108295_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202304521","article-title":"FOXA2 suppression by TRIM36 exerts anti-tumor role in colorectal cancer via inducing NRF2\/GPX4-regulated ferroptosis","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"issue":"7661","key":"10.1016\/j.phrs.2026.108295_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2026.108295_bib71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41589-023-01512-1","article-title":"CGI1746 targets \u03c31R to modulate ferroptosis through mitochondria-associated membranes","volume":"20","author":"Zhang","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.phymed.2015.11.006","article-title":"Apoptosis and necroptosis induced by stenodactylin in neuroblastoma cells can be completely prevented through caspase inhibition plus catalase or necrostatin-1","volume":"23","author":"Polito","year":"2016","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.phrs.2026.108295_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101082","article-title":"VX-765 inhibits pyroptosis and reduces inflammation to prevent acute liver failure by upregulating PPAR\u03b1 expression","volume":"28","author":"Jiao","year":"2023","journal-title":"Ann. Hepatol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108295_bib74","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.3390\/cancers13184699","article-title":"Metabolic flexibility is a determinant of breast cancer heterogeneity and progression","volume":"13","author":"Fukano","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.phrs.2026.108295_bib75","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41419-022-05512-2","article-title":"Blockage of Nrf2 and autophagy by L-selenocystine induces selective death in Nrf2-addicted colorectal cancer cells through p62-Keap-1-Nrf2 axis","volume":"13","author":"Hsu","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib76","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.immuni.2025.11.018","article-title":"Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation","volume":"59","author":"Wientjens","year":"2026","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib77","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-025-02357-x","article-title":"Lipid metabolism in homeostasis and disease","volume":"11","author":"Li","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","article-title":"The interaction between ferroptosis and lipid metabolism in cancer","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"14","key":"10.1016\/j.phrs.2026.108295_bib79","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2026.108295_bib80","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrm2335","article-title":"Lipid signalling in disease","volume":"9","author":"Wymann","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108295_bib82","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","article-title":"Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance","volume":"13","author":"Rozengurt","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108295_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/2159-8290.CD-12-0018","article-title":"Negative feedback and adaptive resistance to the targeted therapy of cancer","volume":"2","author":"Chandarlapaty","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108295_bib84","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bjc.2017.421","article-title":"MTOR inhibitor-based combination therapies for pancreatic cancer","volume":"118","author":"Hassan","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108295_bib85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.apsb.2023.08.012","article-title":"Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer","volume":"14","author":"Ling","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2026.108295_bib86","article-title":"G-quadruplex-modular CpG nanoplatform drives multi-pathway immunity for abscopal chemoimmunotherapy","author":"Sun","year":"2026","journal-title":"Adv. Mater."},{"issue":"22","key":"10.1016\/j.phrs.2026.108295_bib87","doi-asserted-by":"crossref","first-page":"18512","DOI":"10.1021\/jacs.4c17920","article-title":"RNA editing-mediated correction of TP53 nonsense mutations via lipid nanoparticle-delivered circular ADAR-recruiting RNAs","volume":"147","author":"Wang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"7_Suppl.","key":"10.1016\/j.phrs.2026.108295_bib88","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1538-7445.AM2026-3158","article-title":"Abstract 3158: pharmacokinetic and biodistribution evaluation of nebivolol and dasatinib in the 4T1 triple-negative breast cancer model: Implications for drug-drug interaction","volume":"86","author":"Li","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108295_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117465","article-title":"Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): emerging strategies for cancer therapy","volume":"289","author":"Hao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2026.108295_bib90","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acs.jmedchem.3c02133","article-title":"Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in cancer therapy","volume":"67","author":"Shen","year":"2024","journal-title":"J. Med. Chem."},{"issue":"15_suppl).","key":"10.1016\/j.phrs.2026.108295_bib91","article-title":"The scope of possible combination therapy with immunotherapy and targeted therapy","volume":"35","author":"Colli","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:06:09Z","timestamp":1785906369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":91,"alternative-id":["S1043661826002100"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108295","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic dual targeting of mTOR and GLS1 overcomes glutamine-driven resistance in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108295"}}